Search
Metribolone
go.drugbank.com/drugs/DB02998ExperimentalIt binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.
Erythromycin
go.drugbank.com/drugs/DB00199ApprovedInvestigationalVet approvedErythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spi...
Human Umbilical Cord Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15726InvestigationalThe cells are extracted by either the explant or the enzymatic digestion method, though neither method has been characterized as the ‘standard’ thus far.
N-Acetylglucosamine
go.drugbank.com/drugs/DB00141ApprovedInvestigationalNutraceuticalThe N-acetyl derivative of glucosamine.
RGN6024
go.drugbank.com/drugs/DB33059ExperimentalRGN6024, also known as RGN-6024 or RGNi6024, is a synthetic small-molecule tubulin destabilizer from Reglagene. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.
AICA ribonucleotide
go.drugbank.com/drugs/DB01700InvestigationalThe drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]
Ferric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalIron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells.
Olokizumab
go.drugbank.com/drugs/DB13127InvestigationalIL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome
SUVN-502
go.drugbank.com/drugs/DB06140InvestigationalSUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer